Acta Ophthalmologica最新文献

{"title":"The impacts of high refractive errors on self-reported visual function and visual concern","authors":"Jens Riis Møller,&nbsp;Arevak Saruhanian,&nbsp;Jens Rovelt,&nbsp;Josefine Freiberg,&nbsp;Marcel Reimann,&nbsp;Jeppe Nygård Samuelsen,&nbsp;Christina Eckmann-Hansen,&nbsp;Miriam Kolko,&nbsp;Nina Jacobsen,&nbsp;FOREVER Consortium","doi":"10.1111/aos.70120","DOIUrl":"10.1111/aos.70120","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>To examine the association between refractive errors and self-reported visual function and visual concern, considering self-perceived present eyesight, concerns about vision, accomplishing less and limitations in daily activities in an eye-healthy cohort.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A cross-sectional design was used, drawing upon data from a Danish eye and vision cohort, Project FOREVER. Data included refractive measurements and questionnaire responses from participants aged 18 years and above. Logistic regression was applied to investigate the association between self-reported visual function, visual concern and refractive measurements. Refraction was grouped based on spherical equivalent values. Participants were defined as eye-healthy without the presence of self-reported eye disease and a visual acuity of 0.8 or above.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Analyses were done on data from 42 741–42 879 participants (considering only complete responses for each model) and showed that high refractive errors (≤ −6 D and ≥ +6 D) were significantly associated with diminished self-reported visual function and visual concern. High myopia was associated with lower self-perceived present eyesight (OR = 1.89, 95% CI: 1.69–2.11, <i>p</i> &lt; 0.001), increased vision concerns (OR = 1.78, 95% CI: 1.59–1.99, <i>p</i> &lt; 0.001), reduced self-perceived accomplishment (OR = 1.14, 95% CI: 1.01–1.28, <i>p</i> &lt; 0.05) and greater vision-related limitations (OR = 1.44, 95% CI: 1.28–1.61, <i>p</i> &lt; 0.001). High hypermetropia was similarly associated with lower self-perceived present eyesight (OR = 4.23, 95% CI: 3.05–5.87, <i>p</i> &lt; 0.001), increased vision concerns (OR = 2.15, 95% CI: 1.51–3.07, <i>p</i> &lt; 0.001), reduced self-perceived accomplishment (OR = 2.83, 95% CI: 1.99–4.01, <i>p</i> &lt; 0.001) and greater vision-related limitations (OR = 2.78, 95% CI: 1.94–3.97, <i>p</i> &lt; 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The present findings demonstrate a statistically significant negative correlation between high refractive errors and self-reported visual function as well as decreased visual concern. They provide a new perspective on the impact of high refractive errors and highlight the importance of further research aimed at preventing their development.</p>\u0000 </section>\u0000 </div>","PeriodicalId":6915,"journal":{"name":"Acta Ophthalmologica","volume":"104 7","pages":"780-788"},"PeriodicalIF":3.0,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/aos.70120","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147372116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hans Lauber (1876–1952): Cosmopolitan ophthalmologist and his post-WWII extradition request","authors":"Andrzej Grzybowski,&nbsp;Michał Rydzewski,&nbsp;Christopher Theodore Leffler","doi":"10.1111/aos.70152","DOIUrl":"10.1111/aos.70152","url":null,"abstract":"<p>Hans Lauber (1876–1952) was a Swiss-born Austrian ophthalmologist whose career spanned Vienna, Warsaw and Kraków. Once a celebrated scholar and surgeon, Lauber is now a largely forgotten figure in the history of European ophthalmology. This study reconstructs his complex biography, emphasizing his appointment at the University of Warsaw, the role of the John Warden Foundation and the controversies surrounding his wartime activities. Lauber was the author of at least 79 publications, including five textbooks, and was one of the pioneers in the study of visual field physiology and pathology, as well as a co-developer of perimetry standards. He designed his own diagnostic instruments, including a perimeter, a light-spot projector and a red-free fundus examination lamp. From 1931 to 1940, he led the Department of Ophthalmology of the University of Warsaw, in Poland, and between 1939 and 1940, he served as Dean of the Faculty of Medicine at this university. With financial backing from the US-based John Warden Foundation, he modernized the Warsaw Department of Ophthalmology. During the German occupation of Poland, Lauber directed the Jagiellonian University Ophthalmology Department in Kraków, leading to post-war allegations of collaboration and unethical behaviour. Arrested in Austria in 1946, he was never extradited to Poland; the charges were dropped for lack of conclusive evidence. Lauber's life reflects the tension between scientific achievement and moral ambiguity in an era of political turmoil. His story illuminates the fragile boundary between medicine, ethics and history in 20th-century Europe.</p>","PeriodicalId":6915,"journal":{"name":"Acta Ophthalmologica","volume":"104 7","pages":"828-833"},"PeriodicalIF":3.0,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147728033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence of myopia and 10-year change in refractive error and axial length: The Shahroud Eye Cohort Study","authors":"Carla Lanca,&nbsp;Mohammad Hassan Emamian,&nbsp;Abolfazl Emamian,&nbsp;Andrzej Grzybowski,&nbsp;Hassan Hashemi,&nbsp;Akbar Fotouhi","doi":"10.1111/aos.70115","DOIUrl":"10.1111/aos.70115","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>To describe the 10-year incidence of myopia and change in ocular biometry in older adults and their association with risk factors for myopia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The Shahroud Eye Cohort Study is a prospective single-centre cohort study conducted in Iran. Baseline and follow-up eye assessments were conducted in 2009 and 2019. A total of 5190 participants aged 40–64 years attended the baseline assessment. Refractive data from both visits were available in 6239 eyes. The main outcomes were incidence of myopia, change in spherical equivalent refraction (SER) and axial length (AL).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Mean SER shifted from −0.35 ± 1.44 D at baseline to 0.08 D ± 1.67 D at follow-up (SER change: 0.43 ± 0.69 D). Males had more negative baseline SER than females (−0.41 D vs. −0.31 D, <i>p</i> = 0.009) and were more myopic at follow-up (−0.07 D vs. 0.18 D, <i>p</i> &lt; 0.001). The 10-year myopia incidence was 4.60% (95% CI, 3.91–5.40). In myopic eyes, changes in SER were 0.27 D, and in AL 0.04 mm. Predictors of a myopic shift (≤−0.5 D) were longer baseline AL (odds ratio [OR], 1.30; 95% CI, 1.04–1.62), male sex (OR, 1.66; 95% CI, 1.14–2.42), older age (55–59 years: OR 2.26; 95% CI 1.31–3.89; 60–64 years: OR 3.56; 95% CI 1.79–7.08, vs. 40–44 years), low economic status (OR 1.62; 95% CI 1.05–2.50) and baseline SER (OR: 0.15; 95% CI 0.09–0.24).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In this community-based sample, the predominant refractive trend over 10 years was a hyperopic shift, while the incidence and progression of myopia were low.</p>\u0000 </section>\u0000 </div>","PeriodicalId":6915,"journal":{"name":"Acta Ophthalmologica","volume":"104 7","pages":"789-801"},"PeriodicalIF":3.0,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147571735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of visual acuity, intraocular pressure and pain in neovascular glaucoma.","authors":"Gilbert Simons, Mikael von Fersen, Alexandra Dahlberg, Ville Vartiainen, Paula Summanen, Mika Harju","doi":"10.1111/aos.70248","DOIUrl":"https://doi.org/10.1111/aos.70248","url":null,"abstract":"<p><strong>Purpose: </strong>To identify factors associated with best-corrected visual acuity (BCVA), intraocular pressure (IOP) and ocular pain in neovascular glaucoma (NVG).</p><p><strong>Methods: </strong>The retrospective cohort included all patients diagnosed with NVG during 2008-2024 at Helsinki University Hospital, Finland. Linear mixed-effects models used pre-specified covariates, whereas exploratory machine-learning models used all longitudinal data, including biomicroscopic findings.</p><p><strong>Results: </strong>The cohort comprised 626 patients (median follow-up 24 months). Follow-up BCVA was worse in eyes with worse baseline BCVA. A closed anterior chamber angle was associated with 0.13 logarithm of the minimum angle of resolution worse BCVA (95% confidence interval, CI, 0.02-0.23). Age, sex and comorbidity were largely not associated with the outcomes. Glaucoma drainage devices showed the greatest initial IOP reduction (-10.2 mmHg, 95% CI, -11.9 to -8.6), followed by transscleral cyclophotocoagulation (TSCPC, -4.7 mmHg, 95% CI, -5.8 to -3.7) and peripheral retinal cryotherapy (-2.2 mmHg, 95% CI, -3.1 to -1.4). TSCPC and cryotherapy were also associated with less pain (odds ratios 0.51 and 0.46, 95% CI, 0.36-0.74 and 0.34-0.63). Panretinal photocoagulation and anti-vascular endothelial growth factor injections showed smaller IOP reductions, with pain reduction for panretinal photocoagulation only. Machine learning added no findings beyond the mixed models.</p><p><strong>Conclusion: </strong>Treatments were associated with lower IOP and less pain but not with better BCVA, which baseline severity largely explained. Cryotherapy, seldom reported in NVG, showed comparable associations. IOP control and pain relief may therefore remain realistic goals when visual prognosis is poor. Confounding by indication remains possible.</p>","PeriodicalId":6915,"journal":{"name":"Acta Ophthalmologica","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149102583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intravitreal faricimab in patients with nAMD: French data from the Fight Retinal Blindness! Registry.","authors":"Eloi Debourdeau, Déborah Harboun, Pierre-Henry Gabrielle, Yohei Hashimoto, Chloe Chamard, Frederic Michon, Benjamin Wolff, Héloïse Torres-Villaros, Audrey Giocanti-Auregan, Mark Gillies, Catherine Creuzot-Garcher, Vincent Daien","doi":"10.1111/aos.70251","DOIUrl":"https://doi.org/10.1111/aos.70251","url":null,"abstract":"<p><strong>Purpose: </strong>To assess real-world outcomes of intravitreal faricimab in French patients with neovascular age-related macular degeneration (nAMD) previously treated with vascular endothelial growth factor (VEGF) inhibitors using data from the Fight Retinal Blindness! (FRB!) Registry.</p><p><strong>Methods: </strong>Retrospective analysis of prospectively collected FRB! Registry data (November 2023-March 2026) on eyes switched to faricimab from other VEGF inhibitors.</p><p><strong>Primary endpoint: </strong>change in injection interval at 12 months. Secondary endpoints: macular neovascularization (MNV) inactivation, visual acuity (VA), injections, switch-off, safety. Mixed-effects models assessed baseline predictors of interval change and loading-dose effect on MNV inactivation.</p><p><strong>Results: </strong>We included 222 eyes (169 patients; mean [SD] age 81.4 [7.8] years; VA 64.6 [19.3] letters; interval 5.9 [3.5] weeks; 26.2 prior injections); 143 (64.4%) were 12-month completers. Mean interval increased from 6.0 to 8.4 weeks (p < 0.001), with a greater gain in inactive (Δ +4.0 weeks) than active eyes (Δ +1.7 weeks; p = 0.033). VA remained stable (Δ -0.8 letters; p = 0.28). Inactive MNV rose from 36% to 60% (p < 0.001); 50% of active eyes achieved inactivation. After adjustment, MNV activity at switch was the only predictor of interval reduction (vs. inactive: SRFl only, β = -2.8 weeks, p = 0.015; IRF/haemorrhage, β = -2.4 weeks, p = 0.020). A loading dose was not associated with interval extension (p = 0.59) or MNV inactivation (p = 0.50). Intraocular inflammation occurred in 5 eyes (2.3%).</p><p><strong>Conclusion: </strong>Macular neovascularization (MNV) inactivation and modest interval extension were observed in active eyes; inactive eyes showed a larger interval extension. Loading dose was not associated with better outcomes in this observational cohort. Safety was acceptable.</p>","PeriodicalId":6915,"journal":{"name":"Acta Ophthalmologica","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149102536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of retinal break location on surgical outcomes in primary uncomplicated rhegmatogenous retinal detachment: Superior versus inferior breaks.","authors":"Ioanna Dimakopoulou, Michael Georgopoulos, Philipp Toubia Scholz, Jakob Kraiger, Johannes Iby, Sam Hedo, Stefan Sacu, Georgios Mylonas","doi":"10.1111/aos.70249","DOIUrl":"https://doi.org/10.1111/aos.70249","url":null,"abstract":"<p><strong>Purpose: </strong>To compare the anatomical and functional outcomes of pars plana vitrectomy (PPV) for primary uncomplicated rhegmatogenous retinal detachment (RRD) with superior versus inferior retinal breaks.</p><p><strong>Methods: </strong>This retrospective study included 675 eyes of 675 patients, of which 476 had exclusively superior breaks and 199 had at least one inferior break. Patients underwent primary PPV with air or gas endotamponade (SF₆, C₂F₆ or C₃F₈) between January 2015 and March 2025. The primary outcome was single-surgery anatomical success at 6 months. Redetachment-free survival was analysed using Kaplan-Meier estimates and the log-rank test. Secondary analyses included final anatomical success, tamponade choice, concurrent phacoemulsification and postoperative best-corrected visual acuity.</p><p><strong>Results: </strong>Six-month anatomical status was evaluable in 489 eyes. Single-surgery anatomical success (SSAS) was achieved in 90.0% of eyes with superior breaks compared with 78.3% of eyes with inferior breaks (p < 0.001). After adjustment for symptom duration, lens status, retinal-detachment extent, number of retinal breaks and tamponade agent, inferior-break location remained associated with lower odds of success (adjusted OR 0.46, 95% CI 0.22-0.98; p = 0.044). At final follow-up, success rates were 91.6% and 83.9%, respectively (p = 0.003). Redetachment-free survival was significantly lower in eyes with inferior breaks (log-rank p = 0.001). No significant association between concurrent phacoemulsification and anatomical success was detected, although the combined-surgery subgroups were small. Final visual acuity was similar in macula-on detachments. In macula-off detachments, the statistically significant difference favouring superior breaks was approximately 0.11 logMAR and of limited clinical relevance.</p><p><strong>Conclusions: </strong>The presence of at least one inferior retinal break was associated with lower 6-month anatomical success and reduced redetachment-free survival. The findings regarding concurrent phacoemulsification and tamponade choice should be interpreted cautiously because of limited subgroup sizes.</p>","PeriodicalId":6915,"journal":{"name":"Acta Ophthalmologica","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149102549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insights into the modulation of age-related macular degeneration: Molecular and systems-level perspectives","authors":"Hanna Heloterä","doi":"10.1111/aos.70239","DOIUrl":"https://doi.org/10.1111/aos.70239","url":null,"abstract":"<p>In developed countries, age-related macular degeneration (AMD) is the leading cause of visual impairment in the aging population. Understanding of its pathogenesis is limited and the number of patients is predicted to continue rising. AMD is classified into two main forms: dry and neovascular AMD (dAMD and nAMD, respectively). Dry AMD is the most prevalent form (80–90%) of AMD cases and has no approved treatment in Europe. Neovascular AMD (10–20% of AMD cases) is treated with frequent intravitreal injections with medicines intervening with vascular growth, but unfortunately, treatment is not curative and only a portion of patients respond to the current treatments.</p><p>Increasing number of patients will create a challenge to the healthcare system and will underline the need to find either novel, more durable treatment options or ways to intervene with the disease course already in its early stages and prevent or delay disease escalation. Thus, understanding factors behind development of the disease and treatment response is important. Currently, the information on the factors influencing the progression and incidence of the disease is fragmented and does not provide sufficient tools for individualised patient care. In this study, our aim was to create a deeper understanding of factors modulating development and progression of AMD.</p><p>By analysing data from nAMD patients treated in Kuopio University Hospital, we were able to identify that heavy smoking and high BMI increase the probability for earlier emergence of nAMD, while the presence of intraretinal fluid (IRF) resulted in a fast-progressing disease. We also observed a relationship between IRF and the appearance of subretinal drusenoid deposits, HRF and retinal atrophy. Thus, we observed that IRF plays a role in the escalation of the disease towards non-reversible changes in retinal anatomy.</p><p>By analysing serum RNA profile of nAMD patients, we observed that the RNA profile of nAMD patients corresponds with anatomical changes observed in the retinal fluid compartments as well as atrophic changes in retinal layers. Especially, thioredoxin-related transmembrane protein 4 (TMX4) was identified as a protein whose function during AMD development should be evaluated more in detail in the future.</p><p>Moreover, long-term follow-up of women living in the North Savo region revealed the role of systemic components during AMD progression and showed that people with long-term corticosteroid and immunosuppressant use have an increased risk for developing AMD. Our results highlight that further research on how systemic components behind corticosteroid and immunosuppressant use modulate AMD progression is needed.</p><p>Thus, results of this study build more evidence from factors modulating AMD development and progression. Giving guidance to future analyses in a situation where comprehensive understanding from factors influencing AMD progression and development are lacking.</p>","PeriodicalId":6915,"journal":{"name":"Acta Ophthalmologica","volume":"104 S293","pages":"S4-S35"},"PeriodicalIF":3.0,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/aos.70239","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149099448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aqueous chlorhexidine versus povidone-iodine for ocular antisepsis: A systematic review and meta-analysis.","authors":"Hande Coskun, Katrine Najah Mikha, Christian Rasmussen, Jens Rovelt, Gianni Virgili, Miriam Kolko","doi":"10.1111/aos.70242","DOIUrl":"https://doi.org/10.1111/aos.70242","url":null,"abstract":"<p><p>This systematic review and meta-analysis aimed to compare aqueous chlorhexidine (AqCHX) with povidone-iodine (PI) for ocular antisepsis in preventing post-procedural endophthalmitis (primary outcome) and to evaluate antimicrobial efficacy and patient-reported pain (secondary outcomes). A systematic search of PubMed, Embase and Web of Science was conducted on 26 November 2024 and updated on 25 June 2025. Randomised controlled trials (RCTs) and non-randomised studies (NRS) comparing AqCHX with PI for ocular antisepsis were included. Risk of bias was assessed using RoB 2 for RCTs and ROBINS-I for NRS. Meta-analyses were conducted using random-effects models. Endophthalmitis and microbiological culture positivity were reported as odds ratios (ORs), binary pain outcomes as risk ratios (RRs) and continuous pain outcomes as standardised mean differences (Hedges' g), each with 95% confidence intervals (CIs). The certainty of evidence was assessed using GRADE. Eight studies were included, comprising four RCTs and four NRS. Across three large NRS, endophthalmitis rates were low in both groups (0.024% with AqCHX vs. 0.025% with PI), with no statistically significant difference between AqCHX and PI (OR 0.80; 95% CI 0.54 to 1.19; I² = 0%). For microbiological culture positivity, pooled results from three RCTs and one NRS showed no significant difference between AqCHX and PI (OR 1.06; 95% CI 0.61 to 1.83; I² = 0%). The risk of pain or pain-related ocular symptoms was lower with AqCHX than with PI (RR 0.22; 95% CI 0.14 to 0.33; I² = 0%) and pain intensity also favoured AqCHX, although heterogeneity was substantial (Hedges' g = -1.83; 95% CI -2.54 to -1.13; I² = 77.3%). Certainty of evidence was rated as moderate across all outcomes. AqCHX showed comparable effectiveness to PI for ocular antisepsis while being associated with better tolerability. However, conclusions regarding endophthalmitis are limited by the reliance on NRS and the very low event rate, leaving uncertainty about the magnitude of any difference between treatments. Further well-designed, adequately powered studies are needed to clarify their comparative effectiveness and tolerability.</p>","PeriodicalId":6915,"journal":{"name":"Acta Ophthalmologica","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149102585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A genetic and historical perspective on the origins of keratitis fugax hereditaria.","authors":"Annamari T Immonen, Sara P Luostarinen, Päivi Lahermo, Sabita Kawan, Kati Donner, Joseph D Terwilliger, Michael P Backlund, Joni A Turunen","doi":"10.1111/aos.70238","DOIUrl":"https://doi.org/10.1111/aos.70238","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the genetic and genealogical background of keratitis fugax hereditaria (KFH), a periodic corneal disease caused by the heterozygous pathogenic variant c.61G>C in the NLRP3 gene. KFH is characterized by recurrent unilateral autoinflammatory attacks alternating between the eyes and permanent corneal opacities.</p><p><strong>Methods: </strong>Single-nucleotide polymorphism genotyping was performed in 91 individuals from 29 families. Phased haplotypes and recombination breakpoints around the NLRP3 locus were analysed. Genealogical data were collected from 32 Finnish families with KFH, including 107 genetically confirmed patients, and extended to 2756 ancestors using interviews, population registers and historical church records.</p><p><strong>Results: </strong>All families shared a common haplotype surrounding the disease variant, although centromeric and telomeric recombination breakpoints were variable. Differences in common haplotype lengths were consistent with varying degrees of relatedness. Genealogical data were complete for 11 families and partial for 17. Ancestral birthplaces clustered in southwestern Finland, and several families shared distant common ancestors from the mid-to-late 1600s, forming four principal lineages originating from a restricted geographic area.</p><p><strong>Conclusion: </strong>The NLRP3 c.61G>C variant likely originated in southwestern Finland and appears to have been present in the population for at least 350 years. Genealogical reconstruction and haplotype analysis support a single ancestral origin, followed by lineage-specific divergence and regional expansion. In the context of Finland's population history, these findings indicate long-term regional enrichment of the variant and provide a historical framework for understanding its present-day distribution.</p>","PeriodicalId":6915,"journal":{"name":"Acta Ophthalmologica","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148975500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety of intravitreally applied epidermal growth factor receptor antibody panitumumab.","authors":"Mukharram M Bikbov, Gyulli M Kazakbaeva, Leisan I Gilemzianova, Songhomitra Panda-Jonas, Frank G Holz, Jost B Jonas","doi":"10.1111/aos.70235","DOIUrl":"https://doi.org/10.1111/aos.70235","url":null,"abstract":"<p><strong>Purpose: </strong>To examine the safety of the epidermal growth factor (EGF) receptor antibody panitumumab intravitreally applied in patients with myopic macular degeneration (MMD) or neovascular age-related macular degeneration (AMD).</p><p><strong>Methods: </strong>Patients with MMD stage 4 underwent repeated intravitreal panitumumab injections in escalating doses, and patients with neovascular AMD received combined intravitreal ranibizumab/panitumumab injections, with single ranibizumab injections applied in between.</p><p><strong>Results: </strong>The study included 28 patients. In the first cohort, 11 highly myopic patients with MMD stage 4 (age: 66.8 ± 6.3 years) received intravitreal panitumumab injections in doses of 0.6 mg (4 eyes; 1 × 1 injection, 3 × 2 Injections), 1.2 mg (4 eyes; 1 × 1 injection; 2 × 2 injections; 1 × 3 injections) and 1.8 mg (3 eyes; 1 × 1 injection, 2 × 2 injections), respectively, in intervals of 3.6 ± 1.8 months (first to second injection), and 4.7 months (second to third injection). At 3.7 ± 0.4 years (median: 3.6 years; range: 3.5-4.7 years) after the first injection, ten patients were re-examined, with no change in axial length (30.6 ± 1.0 vs. 30.7 ± 1.3; p = 0.66). A second cohort included 17 eyes with neovascular AMD and receiving bimonthly combined panitumumab/ranibizumab (1.2 mg/0.5 mg) injections (mean: 2.4 ± 0.5 injections). The mean follow-up period was 11.0 ± 1.0 months (median: 11 months; range: 6-14 months). In none of the eyes of the first and second cohort, treatment-related systemic or intraocular adverse events were noted. Ocular side effects were hyposphagmata at the injection sites. Signs of intraocular inflammation were not detected in any eye. The morphology of the optic nerve head did not change significantly, nor did the IOP (14.5 ± 4.3 mmHg vs. 13.5 ± 1.5 mmHg; p = 0.30).</p><p><strong>Conclusions: </strong>Repeated intravitreal panitumumab applications in various doses, single or combined with ranibizumab, were not associated with severe ocular or systemic side effects.</p>","PeriodicalId":6915,"journal":{"name":"Acta Ophthalmologica","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148975458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}